De novo autoimmune hepatitis after liver transplantation

Journal of Hepatology

Volumn 40, Issue 1, 2004, Pages 3-7

  Mieli Vergani, Giorgina ^a   Vergani, Diego ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CALCINEURIN INHIBITOR; CD4 ANTIGEN; CYCLOSPORIN A; CYTOCHROME P450 2D6; EPITOPE; GLUTATHIONE; IMMUNOGLOBULIN G; MITOCHONDRION ANTIBODY; MYOSIN; PREDNISOLONE; SMOOTH MUSCLE ANTIBODY; TACROLIMUS;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; DRUG BLOOD LEVEL; ENZYME BLOOD LEVEL; GRAFT SURVIVAL; HLA SYSTEM; HUMAN; LIVER BIOPSY; LIVER TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME;

EID: 0347950971     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2003.10.022     Document Type: Review

References (34)

1. Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PT, Rela M, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351:409-413.
2. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31: 929-938.
3. Conti F, Dousset B, Levillayer H, Gruska I, Weill B, Calmus Y. Autoantibodies after liver transplantation: a marker of allograft disease. J Hepatol 1997;25:150 (abstract).
4. Andries S, Casamayou L, Sempoux C, Burlet M, Reding R, Bernard Otte J, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation 2001;72:267-272.
5. Hernandez HM, Kovarik P, Whitington PF, Alonso EM. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr 2001;32:131-136.
6. Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001;34:464-470.
7. Gupta P, Hart J, Millis JM, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation 2001;71:664-668.
8. Spada M, Bertani A, Sonzogni A, Petz W, Riva S, Torre G, et al. A cause of late graft dysfunction after liver transplantation in children: de-novo autoimmune hepatitis. Transplant Proc 2001;33: 1747-1748.
9. Salcedo M, Vaquero J, Banares R, Rodriguez-Mahou M, Alvarez E, Vicario JL, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002;35:349-356.
10. Dunn MJ, Rose ML, Latif N, Bradd S, Lovegrove C, Seymour C, et al. Demonstration by western blotting of antiheart antibodies before and after cardiac transplantation. Transplantation 1991;51:806-812.
11. Dunn MJ, Crisp SJ, Rose ML, Taylor PM, Yacoub MH. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet 1992;339:1566-1570.
12. Joyce S, Mathew JM, Flye MW, Mohanakumar T. A polymorphic human kidney-specific non-MHC alloantigen. Its possible role in tissue-specific allograft immunity. Transplantation 1992;53: 1119-1127.
13. Dubel L, Farges O, Sato Y, Bismuth H. Development of anti-tissue antibodies in the rat liver transplant model. Transplantation 1998;65: 1135-1137.
14. Fedoseyeva EV, Tam RC, Popov IA, Orr PL, Garovoy MR, Benichou G. Induction of T cell responses to a self-antigen following allotransplantation. Transplantation 1996;61:679-683.
15. Fedoseyeva EV, Zhang F, Orr PL, Levin D, Buncke HJ, Benichou G. De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process. J Immunol 1999;162: 6836-6842.
16. Dubel L, Farges O, Johanet C, Sebagh M, Bismuth H. High incidence of antitissue antibodies in patients experiencing chronic liver allograft rejection. Transplantation 1998;65:1072-1075.
17. Salcedo M, Pons JA, Sousa JM, Rimola A, Suarez F, Banares R, et al. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2001;34:49 (abstract).
18. Evans HM, McKiernan PJ, Beath SV, De Ville de Goyet J, Hubscher SG, Kelly DA. Progressive liver pathology in long term survivors of paediatric liver transplantation. Hepatology 2001;34:246 (abstract).
19. Hadzic N, Srinivasan R, Rela M, Ma Y, Heaton N, Vergani D, et al. De novo autoimmune hepatitis after liver transplantation in children; a single centre experience. Hepatology 2003;38:202A.
20. Hadzic N, Ma Y, Srinivasan R, Cheeseman P, Mieli-Vergani G, Vergani D. Possible predictive and diagnostic role of anti-SLA antibodies in de novo autoimmune hepatitis after liver transplantation. Hepatology 2003;38:364A.
21. Clemente MG, Vajro P, Musu MP, Cicotto L, Ciccimarra E, Mandato C, et al. Autoimmune manifestations in children transplanted for non-autoimmune liver diseases. J Hepatol 2001;34:45 (abstract).
22. Mieli-Vergani G, Vergani D. Progress in pediatric autoimmune hepatitis. Semin Liver Dis 1994;14:282-288.
23. Jones DE, James OF, Portmann B, Burt AD, Williams R, Hudson M. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology 1999;30:53-57.
24. Tan CK, Sian Ho JM. Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation. Liver Transpl 2001;7:461-465.
25. Molmenti EP, Netto GJ, Murray NG, Smith DM, Molmenti H, Crippin JS, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl 2002;8:519-526.
26. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001;21:225-232.
27. Gao E, Lo D, Cheney R, Kanagawa O, Sprent J. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988;336:176-179.
28. Bucy PB, Yan Xu X, Li J, Huang GQ. Cyclosporin A-induced autoimmune disease in mice. J Immunol 1993;151:1039-1050.
29. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-458.
30. Sakaguchi S, Sakaguchi N. Role of genetic factors in organ-specific autoimmune diseases induced by manipulating the thymus or T cells, and not self-antigens. Rev Immunogenet 2000;2: 147-153.
31. Wu DY, Goldschneider I. Cyclosporin A-induced autologous graft-versus-host disease: a prototypical model of autoimmunity and active (dominant) tolerance coordinately induced by recent thymic emigrants. J Immunol 1999;162:6926-6933.
32. Damoiseaux JG, van Breda Vriesman PJ. Cyclosporin A-induced autoimmunity: the result of defective de novo T-cell development. Folia Biol 1998;44:1-9.
33. Aguilera I, Wichmann I, Sousa JM, Bernardos A, Franco E, Garcia-Lozano JR, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol 2001;126:535-539.
34. Miyagawa-Hayashino A, Haga H, Sakurai T, Shirase T, Manabe T, Egawa H. De novo autoimmune hepatitis affecting allograft but not the native liver in auxiliary partial orthotopic liver transplantation. Transplantation 2003;76:271-272.